Weight loss drugs known as GLP-1 agonists have entered the conversation in professional sports. Serena Williams recently discussed her use of tirzepatide to manage weight after pregnancy, sparking a wider debate about whether these medications belong in an athletic context. While these drugs are effective for weight reduction, they are not currently on the prohibited list maintained by the World Anti-Doping Agency. The organization continues to monitor them to identify potential patterns of misuse.
Experts note that the definition of doping rests on three pillars. A substance is problematic if it improves performance, poses a health risk, or violates the spirit of sport. Scientists remain cautious because there is no direct data on how these drugs affect elite performance. Some researchers suggest that in weight-restricted sports like boxing or wrestling, the ability to control body mass through medication could be viewed as an unfair advantage similar to the use of diuretics.
Beyond weight loss, GLP-1 medications show potential in reducing inflammation and improving metabolic health. Some physicians argue that these secondary effects might create a more efficient metabolic environment for exercise. However, there are significant trade-offs. These drugs act on the brain to suppress appetite, which creates a serious risk of under-fuelling. If athletes do not consume enough energy to support their training, their recovery and performance will suffer. Muscle loss is another documented side effect that could hinder rather than help a professional athlete.
Manufacturers like Novo Nordisk and Eli Lilly state that their products are intended for patients with type 2 diabetes or obesity. They do not support use outside these clinical indications. Despite this, the public advocacy by high-profile figures creates a complex ethical landscape. Critics worry that normalization of these drugs for lifestyle purposes creates pressure on younger athletes. As the scientific community waits for more data, sports governing bodies face the challenge of determining where the line between medical necessity and performance enhancement exists.